BookJonathan M. Meyer, Stephen M. Stahl ; with illustrations by Nancy Muntner.
Contents:
Initiating clozapine
Understanding hematologic monitoring and benign ethnic neutropenia
Binding profile, metabolism, kinetics, drug interactions and use of plasma levels
Managing constipation
Managing sialorrhea
Managing sedation, orthostasis and tachycardia
Managing metabolic adverse effects
Managing seizure risk and stuttering
Fever, myocarditis, interstitial nephritis, DRESS, serositis and cardiomyopathy
Eosinophilia, leukocytosis, thrombocytopenia, thrombocytosis, anemia, hepatic
Function abnormalities
Managing enuresis and incontinence, priapism, venous thromboembolism
Neuroleptic malignant syndrome, tardive dyskinesia and obsessive compulsive disorder
The efficacy story: treatment resistant schizophrenia, psychogenic polydipsia
Treatment intolerant schizophrenia, suicidality, violence, mania and parkinson's disease psychosis
Addressing clozapine positive symptom nonresponse in schizophrenia spectrum
Patients
Discontinuing clozapine and management of cholinergic rebound
Special topics: child and adolescent patients, elderly patients, patients with
Intellectual disability, pregnancy and risk for major congenital malformation, lactation, overdose, postmortem redistribution.